Treatment of metastatic and recurrent cervix cancer with chemotherapy: A randomised trial comparing hydroxyurea with cisdiamminedichloro‐platinum plus methotrexate
- 1 January 1986
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 14 (1), 17-19
- https://doi.org/10.1002/mpo.2950140105
Abstract
In a randomised trial comparing single-agent chemotherapy (hydroxyurea) to combination chemotherapy in advanced cervix cancer, response was seen in 57% (including 13% CR) of patients receiving the combination (DDP + MTX) regimen. Responding patients survived significantly longer (11 months) than either those receiving hydroxyurea or those not responding to combination chemotherapy (4 months). Two patients remain in complete remission for 14+ and 17+ months.Keywords
This publication has 5 references indexed in Scilit:
- Hydroxyurea or placebo combined with radiation to treat stages iiib and iv cervical cancer confined to the pelvisInternational Journal of Radiation Oncology*Biology*Physics, 1979
- USE OF ADRIAMYCIN AND METHOTREXATE IN CARCINOMA OF CERVIX - DEVELOPMENT OF A SAFE EFFECTIVE REGIMEN1978
- Hydroxyurea as a radiation sensitizer in women with carcinoma of the uterine cervixAmerican Journal of Obstetrics and Gynecology, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977
- Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseasesCancer, 1976